Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K.

J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.

2.

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS.

Mol Cancer Ther. 2010 Feb;9(2):489-98. doi: 10.1158/1535-7163.MCT-09-0628. Epub 2010 Feb 2.

3.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC.

Mol Cancer Ther. 2009 Jan;8(1):26-35. doi: 10.1158/1535-7163.MCT-08-0149.

4.

BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.

Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD, Woods JH, Lewis JW, Traynor JR.

Eur J Pharmacol. 2005 Feb 21;509(2-3):117-25.

PMID:
15733546
5.

Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

Neilan CL, Husbands SM, Breeden S, Ko MC, Aceto MD, Lewis JW, Woods JH, Traynor JR.

Eur J Pharmacol. 2004 Sep 19;499(1-2):107-16.

PMID:
15363957
6.

Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia.

Neilan CL, King MA, Rossi G, Ansonoff M, Pintar JE, Schiller PW, Pasternak GW.

Brain Res. 2003 Jun 6;974(1-2):254-7.

PMID:
12742645
7.

Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.

Neilan CL, Janvey AJ, Bolan E, Berezowska I, Nguyen TM, Schiller PW, Pasternak GW.

J Pharmacol Exp Ther. 2003 Aug;306(2):430-6. Epub 2003 Mar 27.

8.

Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.

Neilan CL, Nguyen TM, Schiller PW, Pasternak GW.

Eur J Pharmacol. 2001 May 4;419(1):15-23.

PMID:
11348625
9.

An immortalized myocyte cell line, HL-1, expresses a functional delta -opioid receptor.

Neilan CL, Kenyon E, Kovach MA, Bowden K, Claycomb WC, Traynor JR, Bolling SF.

J Mol Cell Cardiol. 2000 Dec;32(12):2187-93.

PMID:
11112994
10.

3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.

Derrick I, Neilan CL, Andes J, Husbands SM, Woods JH, Traynor JR, Lewis JW.

J Med Chem. 2000 Aug 24;43(17):3348-50.

PMID:
10966754
11.

Supplemental Content

Loading ...
Support Center